Single, Dual and Triple Agonists: A Guide to GLP-1 Research Peptides
If you have followed metabolic research at all in the last few years, you have run into a wall of similar-sounding names: semaglutide, tirzepatide, retatrutide, cagrilintide. They are some of the most-searched compounds in the entire peptide field right now. The thread connecting them is a concept worth understanding: receptor agonism, and specifically the move from single to dual to triple agonists. Here is a clear map of how they relate.
First, what is an “agonist”?
A receptor is a docking site on a cell that triggers a response when the right molecule binds to it. An agonist is a molecule that binds and activates that response. In metabolic research, the receptors of interest sit on pathways that govern blood-sugar signaling, appetite regulation and energy balance. The newest research peptides are designed to switch on one, two, or three of these receptors at once — hence single, dual and triple agonists.
Single agonists: the GLP-1 foundation
The starting point is GLP-1 (glucagon-like peptide-1), an incretin hormone the body releases in response to food. A single agonist such as semaglutide is built to activate the GLP-1 receptor on its own. This was the breakthrough class that put incretin research on the map, and it remains the reference point every newer molecule is compared against.
Dual agonists: adding GIP
Tirzepatide is the headline example of a dual agonist. Alongside GLP-1, it also targets the GIP (glucose-dependent insulinotropic polypeptide) receptor — a second incretin pathway. The research rationale is that engaging two complementary pathways at once may produce signaling effects that are different in magnitude or character from hitting GLP-1 alone. In studies, dual agonism is a major area of interest precisely because of this combination effect.
Triple agonists: the frontier
Retatrutide is the most-discussed triple agonist: it adds a third target, the glucagon receptor, on top of GLP-1 and GIP. Glucagon signaling ties into energy expenditure, so combining all three is one of the most active research questions of 2026. This “more receptors, more signaling complexity” progression — one, then two, then three — is the simplest way to keep the whole family straight.
Where does cagrilintide fit?
Not every new metabolic peptide is a GLP-1 agonist. Cagrilintide is an amylin analog — amylin is a different appetite- and digestion-related hormone. It is frequently studied alongside GLP-1 peptides rather than as a substitute, which is why it shows up in the same conversations. Think of it as a neighboring pathway researchers like to pair with the incretin family.
Why this matters for the lab
For research teams, the single/dual/triple framing is more than trivia — it determines which receptor assays, controls and comparisons a study needs. It also explains the explosion of search interest: each new compound represents a more complex signaling experiment than the last. All of these peptides are supplied as lyophilized powder for reconstitution; our reconstitution calculator covers the concentration math, and every batch ships against a per-batch Certificate of Analysis.
Research use only. All compounds discussed here are sold strictly for laboratory and research purposes and are not for human or veterinary use, consumption, or therapeutic application. This article is educational and does not constitute medical advice.